124 related articles for article (PubMed ID: 33481427)
1. Congenital vascular lesions, could MAPK and PI3K inhibitors pave the way to new therapies?
Bisdorff-Bresson A; Eyries M; Boccara O
Curr Opin Oncol; 2021 Mar; 33(2):95-100. PubMed ID: 33481427
[TBL] [Abstract][Full Text] [Related]
2. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
5. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Campbell M; Allen WE; Sawyer C; Vanhaesebroeck B; Trimble ER
Circ Res; 2004 Aug; 95(4):380-8. PubMed ID: 15242975
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
8. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
10. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
11. Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine.
Zhang Y; Liu M; Wang J; Huang J; Guo M; Zuo L; Xu B; Cao S; Lin X
Curr Drug Targets; 2019; 20(15):1505-1516. PubMed ID: 31376819
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
Rosenberg L; Yoon CH; Sharma G; Bertagnolli MM; Cho NL
Carcinogenesis; 2018 May; 39(5):681-688. PubMed ID: 29538717
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
[TBL] [Abstract][Full Text] [Related]
14. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
